Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6158433 | 1.00 | APP (0.36) | APPNPSR1TSHRTP53NPC1 | |
| SCHEMBL4960967 | 0.87 | LTA4H (0.38) | APPTSHRTP53HTTSMN1; SMN2 | |
| SCHEMBL1611004 | 0.87 | LTA4H (0.38) | APPTSHRTP53HTTSMN1; SMN2 | |
| SCHEMBL1610492 | 0.85 | LTA4H (0.39) | TSHRTP53HTTSMN1; SMN2LTA4H | |
| SCHEMBL7382992 | 0.85 | LTA4H (0.39) | TSHRTP53HTTSMN1; SMN2LTA4H | |
| SCHEMBL3939370 | 0.84 | DNM1 (0.41) | TSHRTP53HTTSMN1; SMN2LTA4H | |
| SCHEMBL8735182 | 0.84 | DNM1 (0.41) | TSHRTP53HTTSMN1; SMN2LTA4H | |
| SCHEMBL26092597 | 0.84 | DNM1 (0.41) | TSHRTP53HTTSMN1; SMN2LTA4H | |
| SCHEMBL1610523 | 0.84 | DNM1 (0.41) | TSHRTP53HTTSMN1; SMN2LTA4H | |
| SCHEMBL17558059 | 0.84 | DNM1 (0.41) | TSHRTP53HTTSMN1; SMN2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1653960-A4 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN INC (US) | 2008-11-26 | — | — | EP | claimed |
| EP-1654225-A4 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2007-11-28 | — | — | EP | claimed |
| EP-1653960-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN INC. (US) | 2006-05-10 | — | — | EP | claimed |
| EP-1654225-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | Amgen, Inc. (US) | 2006-05-10 | — | — | EP | claimed |
| US-20050256161-A1 | Melanin concentrating hormone receptor antagonists | AMGEN INC. | 2005-11-17 | — | — | US | claimed |
| US-20050215526-A1 | Melanin concentrating hormone receptor antagonist | AMGEN, INC. | 2005-09-29 | — | — | US | claimed |
| WO-2005019240-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | AMGEN, INC. (US) | 2005-03-03 | — | — | WO | claimed |
| WO-2005019167-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN, INC. (US) | 2005-03-03 | — | — | WO | claimed |
| EP-0586418-A1 | SUBSTITUTED TRIAZOLINONES | BAYER AG (DE) | 1994-03-16 | — | — | EP | claimed |
| US-5276008-A | Herbicides and plant growth regulators | BAYER AKTIENGESELLSCHAFT (DE) | 1994-01-04 | — | — | US | claimed |
| WO-1992020663-A1 | SUBSTITUTED TRIAZOLINONES | BAYER AKTIENGESELLSCHAFT (DE) | 1992-11-26 | — | — | WO | claimed |
| EP-0502307-A2 | Substituted 4,5-diamino-1,2,4-triazol-3-(thi)ones | BAYER AG (DE) | 1992-09-09 | — | — | EP | claimed |
| CN-113307772-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2024-06-28 | — | — | CN | disclosed |
| WO-2023224055-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN THERAPEUTIC OR PROPHYLACTIC METHOD FOR KIDNEY INJURY, COMBINED MEDICINE CONTAINING SAID PHARMACEUTICAL COMPOSITION, AND CCBL1 INHIBITOR | 学校法人藤田学園 | 2023-11-23 | — | — | WO | disclosed |
| US-11685721-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| CN-113307772-A | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2021-08-27 | — | — | CN | disclosed |
| US-4304718-A | ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-12-08 | — | — | US | disclosed |
| US-4264498-A | REACTED WITH AN ACID, ITS ACID HALIDE, OR ANHYDRIDE IN THE PRESENCE OF BORON TRIHALIDE AND AN ORGANIC BASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-04-28 | — | — | US | disclosed |
| US-4181800-A | ANTIBIOTICS FROM SUBSTITUTED PERHYDRO-S-TRIAZINES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-01-01 | — | — | US | disclosed |
| US-4110329-A | Metallic derivatives of neopinone ketal | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1978-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215526-A1 | Melanin concentrating hormone receptor antagonist | MCHR1, MC1R, NPY1R | APP 1503/4885NPSR1 35/4885TSHR 17/4885 |
| US-20050256161-A1 | Melanin concentrating hormone receptor antagonists | MCHR1, MC1R, NPY1R | APP 1715/4885NPSR1 27/4885TSHR 19/4885 |
| US-11685721-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | APP 1038/4885NPSR1 1144/4885TSHR 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.